223 related articles for article (PubMed ID: 34724958)
1. Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy.
Liontos M; Andrikopoulou A; Koutsoukos K; Markellos C; Skafida E; Fiste O; Kaparelou M; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Zagouri F
J Ovarian Res; 2021 Nov; 14(1):148. PubMed ID: 34724958
[TBL] [Abstract][Full Text] [Related]
2. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
4. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
Gynecol Oncol; 2019 Aug; 154(2):441-448. PubMed ID: 31118141
[TBL] [Abstract][Full Text] [Related]
5. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
[TBL] [Abstract][Full Text] [Related]
6. Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.
Liontos M; Sotiropoulou M; Kaparelou M; Tzannis K; Tsironis G; Kyriazoglou A; Tsiara A; Zakopoulou R; Koutsoukos K; Zagouri F; Thomakos N; Haidopoulos D; Rodolakis A; Dimopoulos MA; Bamias A
Gynecol Oncol; 2020 Jun; 157(3):599-605. PubMed ID: 32173048
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy.
Henriksen JR; Nederby L; Donskov F; Waldstrøm M; Adimi P; Jakobsen A; Steffensen KD
J Ovarian Res; 2020 May; 13(1):59. PubMed ID: 32414391
[TBL] [Abstract][Full Text] [Related]
8. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
9. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
Miao Y; Yan Q; Li S; Li B; Feng Y
Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
[TBL] [Abstract][Full Text] [Related]
10. Association between alteration of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, cancer antigen-125 and surgical outcomes in advanced stage ovarian cancer patient who received neoadjuvant chemotherapy.
Tuntinarawat P; Tangmanomana R; Kittisiam T
Gynecol Oncol Rep; 2024 Apr; 52():101347. PubMed ID: 38419812
[TBL] [Abstract][Full Text] [Related]
11. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
Luo Y; Lee M; Kim HS; Chung HH; Song YS
Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
[TBL] [Abstract][Full Text] [Related]
12. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?
Lawson BC; Euscher ED; Bassett RL; Liu J; Ramalingam P; Zhong Y; Fleming ND; Malpica A
Am J Surg Pathol; 2020 Feb; 44(2):206-213. PubMed ID: 31651523
[TBL] [Abstract][Full Text] [Related]
13. Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy.
Jin H; Zhang G; Liu X; Liu X; Chen C; Yu H; Huang X; Zhang Q; Yu J
World J Surg Oncol; 2013 May; 11():112. PubMed ID: 23705622
[TBL] [Abstract][Full Text] [Related]
14. Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.
Zhang Y; Grant MS; Zhang X; Paraghamian SE; Tan X; Clark LH
J Minim Invasive Gynecol; 2021 Jun; 28(6):1237-1243. PubMed ID: 33248314
[TBL] [Abstract][Full Text] [Related]
15. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
[TBL] [Abstract][Full Text] [Related]
16. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer.
Zhou M; Li L; Wang X; Wang C; Wang D
Cell Physiol Biochem; 2018; 46(1):178-186. PubMed ID: 29587273
[TBL] [Abstract][Full Text] [Related]
18. Effects of neoadjuvant hyperthermic intraperitoneal chemotherapy on chemotherapy response score and recurrence in high-grade serous ovarian cancer patients with advanced disease: A multicentre retrospective cohort study.
Wu MF; Liang JX; Li H; Ye YF; Liang WF; Wang LJ; Zhang BZ; Chen Q; Lin ZQ; Li J
BJOG; 2022 Nov; 129 Suppl 2():5-13. PubMed ID: 36485072
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil-to-lymphocyte ratio as a prognostic factor in advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy.
Salman L; Sabah G; Jakobson-Setton A; Raban O; Yeoshoua E; Eitan R
Int J Gynaecol Obstet; 2020 Jan; 148(1):102-106. PubMed ID: 31571212
[TBL] [Abstract][Full Text] [Related]
20. The role of changes in systemic inflammatory response markers during neoadjuvant chemotherapy in predicting suboptimal surgery in ovarian cancer.
Gülseren V; Çakır İ; Özdemir İA; Sancı M; Gökçü M; Güngördük K
Curr Probl Cancer; 2020 Aug; 44(4):100536. PubMed ID: 31980146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
